OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM

OneDigital Investment Advisors LLC bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,787 shares of the company’s stock, valued at approximately $1,906,000.

Other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after purchasing an additional 1,002 shares during the period. Jones Financial Companies Lllp increased its stake in Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after buying an additional 7,320 shares during the period. Goldman Sachs Group Inc. raised its position in Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after buying an additional 84,151 shares during the last quarter. Caxton Associates LLP purchased a new position in Axsome Therapeutics during the 1st quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Axsome Therapeutics by 29.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,250 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $213.67 on Monday. The stock has a fifty day moving average price of $235.53 and a 200 day moving average price of $205.19. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The stock has a market cap of $11.19 billion, a PE ratio of -56.98 and a beta of 0.65. Axsome Therapeutics, Inc. has a 1 year low of $108.04 and a 1 year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.7 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 643 shares of Axsome Therapeutics stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the transaction, the director owned 30,389 shares in the company, valued at approximately $7,566,861. The trade was a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 200,766 shares of company stock worth $46,685,646 in the last 90 days. Insiders own 20.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on AXSM shares. Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Needham & Company LLC raised their price objective on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $255.00 to $256.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft set a $280.00 target price on Axsome Therapeutics in a research report on Tuesday, May 5th. Finally, TD Cowen increased their target price on Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.60.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.